Literature DB >> 9816340

Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.

V Abetamann1, H F Kern, H P Elsässer.   

Abstract

To explore the putative role of hyaluronan (HA) in tumor invasion in pancreatic cancer, we investigated the expression of the HA receptors CD44s and RHAMM in a panel of human pancreatic cancer cell lines. Expression of CD44s has been found in only 1 of 10 cell lines included in this study. This cell line exhibits a highly differentiated phenotype without any metastatic potential when injected into nude mice. Since it has previously been shown that normal pancreatic duct cells express a high level of CD44s, our results indicate that pancreatic cancer may be accompanied by an almost complete loss of CD44s expression. As demonstrated by PCR amplification, this loss of CD44s expression is due to alternative splicing of CD44 pre-RNA. Although most of the pancreatic cancer cell lines express a complex but identical pattern of variant CD44 gene transcripts, only one higher molecular weight CD44 isoform can be detected in a subset of pancreatic cancer cell lines in Western blot analysis. This variant CD44 molecule represents the epithelial CD44 isoform (CD44v8-v10). When cells are cultured on Matrigel, the expression of additional CD44 variants is induced, suggesting that the extracellular matrix can influence the expression of CD44 isoforms and thereby may facilitate tumor invasion. This induction could be due to a regulatory process in the translation of the CD44 variant mRNAs expressed in pancreatic tumor cells. Molecular cloning of a cDNA encoding human RHAMM reveals that both HA receptors are structurally unrelated. In addition, they share an inverse expression pattern. RHAMM mRNA is overexpressed in pancreatic cancer cell lines exhibiting a poorly differentiated phenotype and a high metastatic potential when injected into nude mice. These results indicate that CD44 and RHAMM differentially contribute to invasion of pancreatic adenocarcinoma; however, these functions still remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816340

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Hyaluronate receptors mediating glioma cell migration and proliferation.

Authors:  Y Akiyama; S Jung; B Salhia; S Lee; S Hubbard; M Taylor; T Mainprize; K Akaishi; W van Furth; J T Rutka
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

2.  Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer.

Authors:  Patricia E Carrigan; Jonathan L Bingham; Subha Srinvasan; Teresa A Brentnall; Laurence J Miller
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

Review 3.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

4.  Hyaluronan receptors in the human ocular surface: a descriptive and comparative study of RHAMM and CD44 in tissues, cell lines and freshly collected samples.

Authors:  Laura García-Posadas; Laura Contreras-Ruiz; Antonio López-García; Sonia Villarón Álvarez; Miguel J Maldonado; Yolanda Diebold
Journal:  Histochem Cell Biol       Date:  2011-11-18       Impact factor: 4.304

5.  Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.

Authors:  Dan Peer; Rimona Margalit
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

6.  Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer.

Authors:  Yoichi Yamada; Naoki Itano; Hisashi Narimatsu; Takashi Kudo; Kyoei Morozumi; Setsuo Hirohashi; Atsushi Ochiai; Minoru Ueda; Koji Kimata
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation.

Authors:  Laura García-Posadas; Laura Contreras-Ruiz; Isabel Arranz-Valsero; Antonio López-García; Margarita Calonge; Yolanda Diebold
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-12       Impact factor: 3.117

8.  Prognostic impact of CD168 expression in gastric cancer.

Authors:  Sumiya Ishigami; Shinichi Ueno; Yuka Nishizono; Masataka Matsumoto; Hiroshi Kurahara; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Hideo Arima; Kita Yoshiaki; Yuko Kijima; Masaki Kitazono; Shoji Natsugoe
Journal:  BMC Cancer       Date:  2011-03-24       Impact factor: 4.430

9.  Hyaluronan-mediated motility receptor expression functions as a prognostic biomarker in uterine carcinosarcoma based on bioinformatics analysis.

Authors:  Hui Sun; Li Ma; Jie Chen
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

Review 10.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.